Collaborative helped a research company transitioning to commercialization identify critical timelines, tasks, milestones and resources required to bring a new drug to market. As part of the project, leaders were given the information and tools they needed and the business began building the strong foundation necessary for a successful launch.
Commercial launch is a critical and complex period in the Life Sciences product life cycle. The transition from clinical development to commercial operations can seem overwhelming as companies face considerable challenges in transforming from an R&D-driven organization to one focused on achieving in-market business and commercial excellence. Core to successful launches is preparing the company for a whole new raft of capabilities, processes, and relationships, and in doing so there are a number of factors included in this checklist that companies should consider and questions they should answer.
IBM Watson Health aims to transform the drug development process for life sciences – from research to commercialization. IBM Watson for Drug Discovery helps accelerate breakthroughs by enabling researchers to quickly analyze, identify, and prioritize new therapeutic targets and drug combinations for future study.
BM Watson Health aims to transform the drug development process for life sciences – from research to commercialization. IBM Watson for Drug Discovery helps accelerate breakthroughs by enabling researchers to quickly analyze, identify, and prioritize new therapeutic targets and drug combinations for future study.
Published By: DocuSign
Published Date: Apr 24, 2018
Life science companies are experiencing a significant transformation in how they bring new products to market.
Organizations must adapt to changes in the marketplace, such as global product commercialization, specialized medicine, new regulations, new payment models, and new technology that are driving more product variety, smaller drug volumes, and shorter product life cycles.
To meet the needs of this new commercial model, life science companies must re-envision the global supply chain and evolve the tools they use to run their business. The supply chain that was designed for launching blockbuster products will not work in the future.
Today, the global supply chain relies on a manual, paper-based process centered on printing documents and sending them via overnight mail, fax, or e-mail with scanned attachments. This time-consuming and costly process is errorprone, tedious for customers and team members, and vulnerable to security and compliance risks.